Through quarterly and members-only meetings, regional and national affiliate joint events, as well as its highly regarded annual Conference, SEMDA
The Southeastern Medical Device Association (SEMDA) is a non-profit association designed to promote medical device companies in the Southeast, provide a means for those companies and inventors to network and build community, and provide them with resources to grow.
SEMDA membership and attendance is limited to those companies and individual working within the field of medical devices, including executives and employees of medical device companies, venture capital and angel investors who invest in medical device companies, physicians and/or engineers starting or running medical device companies, university researchers, and professors or other faculty focused on the medical device space. Service providers to the industry may participate as sponsors.
Founder and CEO, CardioMEMS
Jay S. Yadav, M.D., is the Founder and Chief Executive of CardioMEMS and a consulting cardiologist at the Piedmont Heart Institute. He was the founder of Angioguard (acquired by JNJ) and initial investor and director of SMART Therapeutics (acquired by Boston Scientific). Dr. Yadav is a director of several private medical device and technology companies. He is Co-Chair of the Metro Atlanta Bioscience Leadership Council, Chairman of the Medical Device Committee and a Director of Georgia Bio and The Indus Entrepreneurs. He is an active member of the American Heart Association and Chair of the Atlanta Heart Ball for 2013. Dr. Yadav has authored two books and over two hundred publications and has received numerous honors including the AHA Top Ten Scientific Advances for 2003, Ellis Island Medal of Honor for 2004, Southeast Medical Device Association Entrepreneur of the Year Award for 2010, Association of Telecom Professionals Award 2011 and Ernst and Young Entrepreneur of the Year for Healthcare (Southern Region) for 2011.
Bob joined HMC in September 2008 and serves as a Board Member of Optimal Radiology, WellCentive, and RegisterPatient. He also serves as a board observer for Innovative Biosensors, MaxCyte, OpenQ and CliniPace. In addition to his responsibilities at HMC, he serves as the President-elect of the Southeastern Medical Device Association, Chairman of the Commercialization Sub-Committee for the Birmingham Business Alliance’s Economic Prosperity Committee, a member of the Steering Committee of the Alabama Obesity Institute at the University of Alabama in Birmingham, a member of the investor advisory boards for the Florida High Tech Corridor Council and the Florida Institute for the Commercialization of Public Research. He is a Venture Fellow at the University of Alabama in Tuscaloosa, is a Visiting Executive at Auburn University and is a member of the Board of Directors for the Birmingham Venture Club and the Atlanta Venture Forum. Prior to joining HVP, Mr. Crutchfield served as Senior Vice President/General Manager of the Pharmacy Services Division at U.S. Oncology, a privately held, vertically integrated cancer care provider network. The division was responsible for approximately $2 billion of annual revenue, and under his leadership the division’s EBITDA grew to over $80 million. Bob was also a Senior Executive at Cardinal Health, where he served as Vice President of New Ventures. While with Cardinal Health, he built and launched a new surgical products business unit through licensing of new technologies and the acquisition of Snowden Pencer Instrument Company. In 1994, Bob founded Surgical Innovations and Services, Inc. (SIS), a surgical laser management company. Under his leadership, SIS became a leader in the emerging outsource management sector, with over 300 hospitals and surgery centers under contract with SIS for management oversight and delivery of their surgical laser programs. In 2000, SIS merged with Surgical Laser Technologies, Inc. (SLTI) a publicly traded surgical laser-manufacturing firm. He continued as President of SIS and served as VP of Sales, Marketing and Business Development for SLTI until he exited the company following its acquisition by publicly-traded Photomedex, Inc. Bob has launched five successful new business ventures during his private and corporate career and has led four M&A transactions. He is a graduate of the University of Georgia and holds Bachelor of Science degrees in Political Science and Chemistry.
Ms. Karp has spent over 11 years bringing innovative medical technology from benchtop to bedside. She joined the Global Center for Medical Innovation (GCMI) in 2011 to direct business development activities, build strategic relationships and bring together core members of the medical device ecosystem. GCMI represents the Southeast’s first comprehensive medical device innovation center. It was founded to accelerate the commercialization of innovative medical technology that will improve patient lives and grow a stronger medical device industry in Atlanta and the Southeast. Ms. Karp is working with universities, clinicians, industry, investors and startups focused on innovation, patient care and economic growth. She currently leads all day-to-day operations of the Center. Ms. Karp joined GCMI from Scientific Intake, where she served as the Vice President of Business Development & Strategy, evaluating marketing and distribution opportunities and driving product development projects for the global obesity market. Prior to Scientific Intake, Ms. Karp was Vice President of Corporate Strategy & Finance at ACell, Inc., a regenerative medicine & tissue engineering company based in Columbia, Maryland. At ACell, she led broad range of initiatives including corporate finance, investor relations, strategic & operational planning, business development, regulatory, and reimbursement. Ms. Karp began her career in management consulting and investment banking, and brings considerable US and international experience in strategic planning, business development, financial analysis, and market evaluation in technology related industries. Ms. Karp is President-elect of the Southeastern Medical Device Association (SEMDA) and served as the Co-Chair of the Medical Device Subcommittee of the Metro Atlanta Chamber Bioscience Leadership Council. In addition, she is working closely with Georgia Tech and Children’s Healthcare of Atlanta to commercialize new pediatric technologies. Ms. Karp earned a BBA in International Business from Loyola University and an MBA from the Georgetown University McDonough School of Business.
SEMDA President 2012-2013
Charlie Harrison currently serves as Global COO of Medical Compression Systems, Inc. (MCS), having served MCS in a series of leadership positions since September 2009 and as a Director of its parent Company from 2004 to 2009. MCS is a leader in innovative, non-invasive solutions for the prevention of venous thromboembolism (VTE). Charlie brings extensive marketing and operating experience in driving new product and business commercialization in medical and pharmaceutical markets and has served as an officer and director in both public and private companies. Prior to joining MCS Management Charlie was President, CFO, Director and a Founder of Wynden Pharmaceuticals, Inc., a private pharmaceutical company focused on improving electrolyte management in cardiovascular and diabetes patients. Early in his career, Charlie led Organon’s entry into the surgical muscle relaxant business, where they achieved a market leadership position. Charlie then shifted to lead marketing for Organon Diagnostics and, subsequently, for a division of SmithKline. After SmithKline, Charlie became President, CFO and a Director of Unimed, Inc., a specialty pharmaceutical company focused on Cancer and AIDS therapies, taking the company from a research focus to a direct sales and marketing presence. Subsequently, he served as CEO in the launch of Creative Products Resource, a development company focused on dermatological and other consumer products that was ultimately sold to Dial Corporation. More recently, Charlie ran the therapeutics business of Serologicals Corporation, a division he grew to revenues in excess of $100 million through organic growth and acquisitions. Prior to his involvement with Wynden Pharmaceuticals, Charlie founded and led Critical Strategies, a consulting business that provided commercial and financial strategic advisory support to life science companies, with primary focus on business development. Charlie serves as a Director of the American-Israel Chamber of Commerce, Southeast Region. Charlie received his BS in Mathematics from Pennsylvania State University and his MBA from the University of Massachusetts.
CEO, Advanced Catheter Therapies, Inc.
President, PJ Fitzpatrick Executive Advisory Group, LLC
With 24 years of diverse, entrepreneurial business, and healthcare experience, Paul has a proven track record of delivering results. Senior leadership positions he has held include Founder, CEO, President, Board of Directors, COO and EVP. Paul’s background also includes numerous start-ups, turnarounds, roll-ups, integration of acquired companies, multi-site and state operations, public, private and venture backed financing's, medical devices, clinical and patient care services, international recruiting & staffing, developing numerous strategic alliances, education and completing over 20 M&A transactions with a combined value in excess of $100 million. As president of PJ Fitzpatrick Executive Advisory Group, LLC, Paul provides interim and fractional CEO and Board engagements and advisory services to start-ups, early stage and small healthcare services and medical device companies. Among others, Paul serves as CEO and Director of Advanced Catheter Therapies, Inc., (ACT) in Chattanooga, TN, with responsibility for developing and executing the Company’s business model, strategy and raising $3M of capital. He also serves as a Non-Executive Director and Executive Advisor at QuantuMDx Group Limited, a UK-based early stage R&D medical device company. Paul has served as interim Chief Executive Officer and director of NeoMatrix, LLC and as a consultant with Waveland Capital Group LLC where he monitored Waveland Capital Partners’ portfolio companies. In 2002, he founded and served as President and CEO of I-Medical Staffing, a U.S. based healthcare staffing company that sourced, prepared, and employed highly experienced internationally trained, English-speaking registered nurses for assignments into U.S. healthcare facilities; he executed its merger in 2006 with a large domestic staffing company. Prior to that, Paul was the Executive Vice President and COO and a start-up team member of Healthcare Innovations, Inc., a rehabilitation services company, where he was responsible for mergers and acquisitions and operations. Paul was responsible for and orchestrated its sale in 2001 to a large publicly traded company. From 1994 to 1997, Paul was a Corporate Vice President at Careline, Inc., an emergency medical services rollup company, which had two public offerings raising $160 million, and was eventually acquired for $358 million. His responsibilities included acquisition due diligence, strategic planning and integration. Prior to that, Paul was founder and president of P.J. Fitzpatrick & Associates, Inc., an emergency medical services consulting firm. Paul is a graduate of the Daniel Freeman Hospital Paramedic School, earning his board certification as a National Registered Paramedic, and holds a degree in paramedic technology from Northeastern University in Boston, where he served as an adjunct faculty member for 10 years.
David L. Day joined the Office of Technology Licensing at the University of Florida as Director on April 2, 2001, where he oversees the commercialization efforts for UF through licensing, incubation and related activities. Mr. Day serves on the following Board of Directors & Executive Committees: BioFlorida (where he is also Vice Chairman), the Florida Research Consortium, Southeastern Bio Investors Forum and the Southeast Medical Devices Association (Board only). Mr. Day also serves as Vice-Chair of the Board of Directors and Principal Investigator for the Florida Institute for the Commercialization of Public Research. He is Co-Chair of Innovation Gainesville and UF Center for Pharmacometrics and Systems Pharmacology Strategic Advisory Group Member
Mr. Day received the 2012 Volunteer of the Year Award from the Florida Economic Development Council.
The University of Florida is the top-performing public institution at transferring its research to the marketplace, according to a study by the Milken Institute. In a report by the California-based economic think tank titled “Mind to Market: A Global Analysis of University Biotechnology Transfer and Commercialization,” UF ranked fifth overall on the Institute’s University Technology Transfer and Commercialization Index. UF also finished 4th in the U.S. in FY 2013 with 15 new startups behind the University of California System (55), the University of Texas system (22) and MIT(16). Also reporting to Mr. Day is UF’s incubator program which includes the Florida Innovation Hub at UF and the Sid Martin Biotechnology Incubator. The University of Florida’s Sid Martin Biotechnology Incubator took top honors worldwide in April 2013, when it was named the 2013 Incubator of the Year by the National Business Incubation Association.
Vice President, Metro Atlanta Chamber
David Hartnett is the vice president of bioscience and health IT industry development for Metro Atlanta Chamber’s economic development division. Prior to joining the Chamber, Hartnett served as the president and CEO of Maco Pharma (formerly United Pharma) a privately held medical device/pharmaceutical company based in Duluth, Georgia, headquartered in Lille France. Prior to Maco Pharma, Hartnett was president and CEO of SteriFx Corporation, a specialty chemical company, contracted by U.S. Department of Defense (DARPA). Prior to SteriFx, he was the executive vice president of the North American headquarters of Given Imaging, Inc. Under his leadership the company commercialized the “PillCam” video capsule, a disposable capsule that captures video after it is ingested by the patient. Hartnett helped to raise more than $30 million in a private placement for corporate infrastructure development and product commercialization prior to the company going public in 2001 (GIVN-NASDAQ). Hartnett served as vice president of marketing at ERBE Electrosurgery, the largest manufacturer of electrosurgical systems in the world, where he was responsible for commercial marketing throughout North America. He has also served in a variety of other senior sales and marketing roles for the following companies: Karl Storz Lithotripsy, Genzyme (formerly Deknatel), STERIS (formerly AMSCO) and the XEROX Corporation. He holds a B.A. in speech communication from San Diego State University with a master’s equivalent in marketing through post-graduate studies. He currently serves on the following boards:
American-Israel Chamber of Commerce, Board of Directors
Atlanta Technical College, Board of Advisors
Clayton State University, Board of Advisors
Georgia Bio, Board of Directors
Health IT Leadership Summit, Board of Directors/Co-Founder
Innovation Crescent Regional Partnership, Vice Chairman
Institute for Healthcare Technology, Board of Directors/Co-Founder
Technology Association of Georgia –TAG Health, Board of Advisors
Southeastern Medical Device Association, President Emeritus
Venture Atlanta Coalition, Board of Directors/Co-Founder
Top Kernel, Crackerjack Marketing
Lynn Hood is the Top Kernel at Crackerjack Marketing, an integrated marketing firm that helps medical device, bioscience, high tech and business‐to‐business companies strategically position themselves and increase sales. Crackerjack is the answer for businesses that need a right‐sized solution for their marketing, branding or public relations needs. Lynn has more than 25 years of experience working with agencies and corporations in marketing and communications. Before founding Crackerjack Marketing, she was President of Hood Marketing Solutions for 20 years. Prior to that, Lynn was a senior writer for the Institute of Nuclear Power Operations (INPO) and served as Communications Manager for Oglethorpe Power Corporation. She has also worked with Liberty Life Insurance/Liberty Corporation, Southern Vital Record Center, Pearl River Basin Development District and the Appalachia Health Council, and began her career as a reporter for the Augusta Chronicle‐Herald. Lynn is active in a number of organizations that support Atlanta’s growth. She was a founding member of SEMDA and remains on the Board of Directors after eight years. Lynn is on the Board of Advisors for the Metro Atlanta Chamber, serving on the Bioscience Leadership Council. She is on the Board of Advisors for TAG Health. She received an ABJ from the University of Georgia.
Senior Director, State Government Affairs, Johnson & Johnson
Chief Executive Officer, Claro Scientific, LLC
Tom is the CEO of Claro Scientific, a diagnostic company focused on commercializing an innovative optics-based analytical system for research, manufacturing and medical applications. Claro is located in St. Petersburg, FL. Previously he held several executive leadership roles in the biotechnology, pharmaceutical and consumer products industries. From 1998 through 2007, he worked at Nabi Biopharmaceuticals, a NASDAQ listed life sciences company developing and marketing vaccine and antibody products. His positions included Chief Executive Officer and President (2002-2007), Executive Vice President and Chief Operating Officer (2001-2002), and Senior Vice President, Corporate Services and Chief Financial Officer (1998-2002). From 1988 to 1998, Mr. McLain was employed by Bausch & Lomb, Inc., a global eye care company, where he held various executive positions, including Vice President Business Process Reengineering, Assistant Corporate Controller and Vice President Accounting and Financial Reporting. Before joining Bausch & Lomb, Mr. McLain practiced with the accounting firm of Ernst & Young LLP. In addition Tom has served on several corporate and non-profit boards including Eastman Chemical Company (board member, health safety, environment and security committee chair, audit committee and finance committee member), Nabi Biopharmaceuticals (board member and board chairman), SEMDA (board member), BioFlorida (board member, board chairman and legislative affairs committee chair), Biotechnology Industry Organization (health section governing board, regulatory environment committee and reimbursement committee member), Enterprise Development Corporation (board member) and Rochester General Hospital Foundation (board member, vice-chair and treasurer). Tom is a certified public accountant in New York State. He earned his BA in economics at the College of the Holy Cross and his MBA from the William E. Simon Graduate School of Management at the University of Rochester.
President, Ideal Search Services LLC
Senior Vice President, Scientific Affairs, and Board of Directors, CardioMEMS, Inc.
President and Chief Executive Officer, Southern Research Institute
Arthur J. Tipton, Ph.D., assumed the role of President and CEO of Southern Research Institute on July 1, 2013. He has worked in the pharmaceutical and biotech industry for 25 years, participating in the growth aspects of three start-up companies. The company he founded in 2005 as a Southern Research Institute spin-out company—Brookwood Pharmaceuticals—was acquired by SurModics in August 2007 and then by Evonik in November 2011. At Evonik, Tipton served as Senior Vice President of the Birmingham Division and also led the company’s global drug delivery program.
From 1993 to 2004, Tipton held roles of increasing responsibility at Durect Corporation, including that of Senior Vice President of biodegradable systems, Chief Operating Officer, Vice President of its wholly-owned subsidiary Southern BioSystems, and President of Birmingham Polymers. He was with Atrix Laboratories (now part of QLT Inc.) from 1988 until 1993, as Manager of Polymer Science and Senior Polymer Chemist.
Tipton serves on multiple boards including the Controlled Release Society (CRS), the Birmingham Venture Club, the Economic Development Partnership of Alabama Foundation, and the Biotech Association of Alabama (BioAlabama). He previously served on the boards of the Society for Biomaterials, the American Institute of Medical and Biological Engineers (AIMBE) and the corporate boards of Brookwood Pharmaceuticals and Southern BioSystems. He has led or participated in multiple transactions, including sell-side and buy-side acquisitions and licenses. Tipton has 31 issued U.S. patents, 22 published U.S. patent applications, and numerous foreign equivalents, with more than 70 presentations and publications.
He is a fellow of AIMBE and CRS and was awarded the CRS Distinguished Service Award in 2012. He serves as an external advisor to the Biomedical Engineering Department at University of Alabama at Birmingham (UAB), and volunteers as a mentor and judge in business plan competitions.
Tipton earned a Ph.D. in Polymer Science and Engineering from the University of Massachusetts in Amherst, and a B.S. in Chemistry from Spring Hill College.
Director of Capital Funds, River Cities Capital Funds
Founder, Managing Partner, MedTech-Partners, LLC
Ms. Sinton is a proven medical device and biotech industry executive in both entrepreneurial ventures as well as multi-national corporations with more than 20 years experience. At Given Imaging (NASDAQ: GIVN), she was the original Vice President of Sales and Medical Education who hired and led a field team of 60 + individuals while developing the strategy and leading the commercial launch of the U. S. and Canadian Pillcam™ markets. The Given launch is published in Harvard Business Review. Ms.Sinton’s experience with high-paced mergers and acquisitions includes her role as Vice President of Sales at Imagyn Medical Technologies during its ownership by Credit Suisse First Boston, whose increased field profitability performance led them from bankruptcy to profitability in a little more than a year resulting in its corporate sale to ConMed, Inc. She won multiple Presidents’ Club Awards, including as a Regional Sales Manager during Kohlberg Investments ownership of Deknatel Snowden Pencer, acquired by Genzyme (NASDAQ: GENZ), becoming the Genzyme BioSurgery Division. She began her medical career at Alcon Laboratories, a $10 Billion Swiss based ophthalmic company. Ms. Sinton is the Founder and Managing Partner of MedTech-Partners, a privately held professional service and strategic execution company specializing in corporate operation enhancement and plan development, product commercialization involving both strategy and tactical tools for sales, marketing and distribution, as well as product licensing and strategic sales representation to acquisition targets. MedTech-Partners also develops funding strategies and plan development for start-up, small and mid-cap medical companies in both the US and global markets. She serves on the Board of Directors of The NeuroScience Foundation and is a member of the American Israeli Chamber of Commerce SE Medical Advisory Board. Her involvement in Angel road shows has resulted in raising over $42 million to date. Ms. Sinton holds a BBA in Management from Georgia Southern University, who recognized her contributions to the Medical Industry by awarding her their Alumni in the Spotlight Award. At SEMDA, Ms. Sinton is responsible for strategic growth and organizational development to build membership value, as well as relationships with affiliate organizations. She will also serve as Chair of the 2014 annual SEMDA Conference.